|1.||Schally, Andrew V: 13 articles (01/2011 - 02/2002)|
|2.||Nagy, Attila: 9 articles (02/2006 - 02/2002)|
|3.||Halmos, Gabor: 7 articles (06/2007 - 04/2005)|
|4.||Engel, Jörg B: 6 articles (09/2007 - 04/2005)|
|5.||Keller, Gunhild: 5 articles (07/2006 - 04/2005)|
|6.||Baker, Benjamin: 4 articles (07/2006 - 07/2005)|
|7.||Nagy, A: 4 articles (01/2002 - 02/2000)|
|8.||Schally, A V: 4 articles (01/2002 - 02/2000)|
|9.||Gaiser, Timo: 3 articles (09/2005 - 07/2005)|
|10.||Halmos, G: 3 articles (01/2001 - 02/2000)|
|1.||Prostatic Neoplasms (Prostate Cancer)
02/01/2006 - "Targeted chemotherapy with AN-207 could be considered for treatment of advanced prostate cancer."
05/01/1997 - "Further development of approaches based on targeted cytotoxic analog AN-207 may lead to major improvements in current palliative therapy of prostate cancer."
02/01/2006 - "The effects of AN-207 and AN-201 were investigated in DU-145 androgen independent and LuCaP-35 androgen sensitive human prostate cancers xenografted into nude mice. "
02/01/2006 - "Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207."
02/08/2002 - "Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207."
|2.||Ovarian Neoplasms (Ovarian Cancer)
10/01/2002 - "Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207."
01/01/2001 - "The targeting of AN-207 to ES-2 cells in the presence of LHRH receptor-negative UCI-107 ovarian cancer cells was also evaluated by semi-quantitative polymerase chain reaction (PCR) amplification of microsatellite markers. "
01/01/2001 - "In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses."
05/01/1999 - "Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice."
01/01/2001 - "These results extend our previous findings that AN-207 can be targeted to ovarian cancers and other tumors that express receptors for LHRH. "
04/01/2005 - "AN-207 also significantly suppressed the proliferation in vivo of HEC-1A and RL-95-2 cancers. "
10/01/2002 - "AN-207 caused a significant ( <0.01) 59.5% inhibition in tumor growth while its components were ineffective. "
02/08/2002 - "After 4 weeks of treatment with AN-207, tumor growth was inhibited as shown by a 63% (P<0.01) decrease in tumor volume and a 55% (P<0.05) reduction in tumor weight, compared with controls. "
02/01/2000 - "The growth of MDA-MB-231 tumors in animals given a single dose of AN-207 was inhibited significantly (p = 0.01) for 3 weeks after injection, whereas tumors in all the other groups grew steadily. "
05/01/1997 - "Our work indicates that the cytotoxic analog AN-207 is much less toxic than the antineoplastic radical (AN-201) incorporated, and significantly more active in inhibiting tumor growth. "
|4.||Endometrial Neoplasms (Endometrial Cancer)
04/01/2005 - "Experimental study using athymic nude mice bearing xenografts of HEC-1A and RL-95-2 human endometrial cancers to assess the efficacy and toxicity of AN-152 and AN-207. "
02/18/1997 - "In view of its high selectivity and reduced toxicity, AN-207 could be a potential therapeutic agent for the treatment of tumors that possess receptors for LH-RH such as prostatic, mammary, ovarian, and endometrial cancers."
04/01/2005 - "Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207."
09/01/2007 - "The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers."
04/01/2005 - "Targeted chemotherapy with AN-152 and AN-207 strongly inhibits the growth of human endometrial cancers, which express LHRH receptors, and could provide a new treatment modality for women with advanced endometrial carcinoma."
06/15/1999 - "The results of this study indicate that powerful, targeted cytotoxic LH-RH analogs such as AN-207 could be considered for the treatment of human breast carcinomas that possesses receptors for LH-RH."
10/01/2000 - "Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207."
10/01/2000 - "The effects of AN-207 were investigated in MDA-MB-435 human estrogen-independent breast carcinomas, which express LH-RH receptors. "
06/15/1999 - "A highly potent cytotoxic agent, 2-pyrrolinodoxorubicin (AN-201), was linked to the agonist [D-Lys6]LH-RH to form a cytotoxic LH-RH analog, AN-207, that can be targeted to LH-RH receptors on breast carcinomas. "
05/01/1997 - "The effects of AN-207, a new targeted cytotoxic analog of LH-RH, were evalued in rats bearing hormone-dependent Dunning R-3327-H prostate carcinomas. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|2.||AN 204 (AN 201)
|4.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|10.||Membrane Proteins (Integral Membrane Proteins)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|4.||Palliative Care (Palliative Medicine)